Department of Oral Surgery, Guy's and St Thomas's NHS Foundation Trust, London, UK.
Prim Dent J. 2022 Sep;11(3):108-116. doi: 10.1177/20501684221112512.
Osteoradionecrosis (ORN) and medication-related osteonecrosis of the jaw (MRONJ) are uncommon conditions, however when present they have a significant impact on a patient's quality of life and are notoriously difficult to treat. With medical advances resulting in improved survival rates and increased life expectancy, it is likely that general dental practitioners (GDPs) will more frequently be involved in the oral health management of patients at risk of both ORN and MRONJ. Though management of both diseases is beyond the scope of primary care dentistry, the GDP still has a key role in the patient's overall care. It is therefore important to have a good understanding of these conditions and their consequences for dental treatment in order to provide adequate patient support. Management requires a multidisciplinary approach to treatment and as part of this GDPs are integral in prevention, early recognition and maintenance of oral health following diagnosis. This article aims to refresh the reader's knowledge regarding MRONJ and ORN and support the GDP in managing this patient group.
骨放射性坏死(ORN)和药物相关性颌骨坏死(MRONJ)是不常见的疾病,但当它们发生时,会对患者的生活质量产生重大影响,而且治疗起来非常困难。随着医学的进步,生存率提高,预期寿命延长,普通牙科医生(GDP)可能更频繁地参与到有ORN 和 MRONJ 风险的患者的口腔健康管理中。尽管这两种疾病的治疗都超出了初级保健牙科的范围,但 GDP 仍然在患者的整体护理中发挥着关键作用。因此,了解这些疾病及其对牙科治疗的影响对于为患者提供足够的支持非常重要。治疗需要多学科方法,作为其中的一部分,GDP 在预防、早期发现和诊断后维持口腔健康方面发挥着重要作用。本文旨在更新读者对 MRONJ 和 ORN 的认识,并支持 GDP 管理这一患者群体。